Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review.
Giulia Maria StellaFilippo ScialòChandra BortolottoFrancesco AgustoniVincenzo SanciJessica SaddiLucio CasaliAngelo Guido CorsicoAndrea BiancoPublished in: Cancers (2022)
It is well known that lung cancer relies on a number of genes aberrantly expressed because of somatic lesions. Indeed, the lungs, based on their anatomical features, are organs at a high risk of development of extremely heterogeneous tumors due to the exposure to several environmental toxic agents. In this context, the microbiome identifies the whole assemblage of microorganisms present in the lungs, as well as in distant organs, together with their structural elements and metabolites, which actively interact with normal and transformed cells. A relevant amount of data suggest that the microbiota plays a role not only in cancer disease predisposition and risk but also in its initiation and progression, with an impact on patients' prognosis. Here, we discuss the mechanistic insights of the complex interaction between lung cancer and microbiota as a relevant component of the microenvironment, mainly focusing on novel diagnostic and therapeutic objectives.
Keyphrases
- end stage renal disease
- genome wide
- induced apoptosis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- stem cells
- papillary thyroid
- squamous cell carcinoma
- lymph node
- cell cycle arrest
- ms ms
- randomized controlled trial
- signaling pathway
- young adults
- patient reported outcomes
- copy number
- study protocol
- cell death
- endoplasmic reticulum stress
- transcription factor
- childhood cancer
- double blind
- breast cancer risk